- Home
- VHI vs AUTL Comparison
VHI vs AUTL Comparison
Compare VHI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VHI | AUTL |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 431.2M |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VHI | AUTL |
|---|---|---|
| Price | $14.35 | $1.49 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $8.50 |
| AVG Volume (30 Days) | 9.2K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,077,000,000.00 | $10,120,000.00 |
| Revenue This Year | $33.32 | $84.74 |
| Revenue Next Year | N/A | $65.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $11.44 | $1.15 |
| 52 Week High | $20.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | VHI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 54.72 |
| Support Level | $13.57 | $1.45 |
| Resistance Level | $14.44 | $1.52 |
| Average True Range (ATR) | 0.46 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 52.95 | 80.25 |
Price Performance
Historical ComparisonAbout VHI Valhi Inc.
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.